Typhoid Fever - Pipeline Insight, 2022

DelveInsight's , "Typhoid Fever - Pipeline Insight, 2022," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Typhoid Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Typhoid Fever Understanding

Typhoid Fever: Overview

Typhoid fever is also called enteric fever. It is a prospectively, multisystemic illness that has been a public health problem, especially in the developing world. It is caused by Salmonella typhi and Salmonella paratyphi. Enteric fever is a cumulative term that illustrates both typhoid and paratyphoid fever. Paratyphoid is clinically indistinct from typhoid fever; thus, enteric and typhoid fever are used mutually. Typhoid fever is one of the major causes of mortality and morbidity in overcrowded and unhygienic areas though comprehensive research and public health interventions have decreased the occurrence. The disease course ranges from early gastrointestinal distress to nonspecific systemic illness but ultimately may lead to multiple complications. Salmonella is said to spread by the 'four Fs" (flies, fingers, feces, fomites). Fever characteristically comes in a step-wise pattern (i.e., rises and falls alternatively) followed by headache and abdominal pain.

"Typhoid Fever - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Typhoid Fever pipeline landscape is provided which includes the disease overview and Typhoid Fever treatment guidelines. The assessment part of the report embraces, in depth Typhoid Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Typhoid Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Typhoid Fever.

• In the coming years, the Typhoid Fever market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

• The companies and academics that are working to assess challenges and seek opportunities that could influence Typhoid Fever R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Typhoid Fever treatment market. Several potential therapies for Typhoid Fever are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Typhoid Fever market size in the coming years.

• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Typhoid Fever) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Typhoid Fever Emerging Drugs Chapters

This segment of the Typhoid Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Typhoid Fever Emerging Drugs

EuTCV: EUBIOLOGICS

EuBiologics has successfully developed a next-generation typhoid conjugate vaccine that has longer-lived defenses and higher efficacy by conjugating Vi and CRM197 to induce the B cells and T cells immune response. Currently,it is in Phase II/III stage of clinical trial evaluation.

Entervax: Prokarium

Entervax™, a novel, oral bivalent vaccine against enteric fever, is based on the Vaxonella® platform and is the combination of our proprietary strain ZH9 (Salmonella enterica serovar Typhi ZH9), plus a novel strain modified to express antigens specific to S. Paratyphi A. Currently, it is in Phase I stage of clinical trial evaluation to treat Typhoid fever.

Further product details are provided in the report:

Typhoid Fever: Therapeutic Assessment

This segment of the report provides insights about the different Typhoid Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Typhoid Fever

There are approx. 3+ key companies which are developing the therapies for Typhoid Fever. The companies which have their Typhoid Fever drug candidates in the most advanced stage, i.e. phase II include, EUBIOLOGICS.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Typhoid Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as:

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Typhoid Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Typhoid Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Typhoid Fever drugs.

Typhoid Fever Report Insights

• Typhoid Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Typhoid Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Typhoid Fever drugs?

• How many Typhoid Fever drugs are developed by each company?

• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Typhoid Fever?

• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Typhoid Fever therapeutics?

• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for Typhoid Fever and their status?

• What are the key designations that have been granted to the emerging drugs?

Key Players

• EUBIOLOGICS
• Prokarium
• Indian Immunologicals Ltd
• Achilles Vaccines Srl.
• Enesi Pharma

Key Products

• EuTCV
• Entervax
• Typhoid Conjugate Vaccine